Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
1 Day DSKYF 10.11% DJIA 1.65% S&P 500 1.83% Health Care/Life Sciences 0.69% ...
Daiichi Sankyo Company, Ltd, an innovative global healthcare company, announced that it will pay Glycotope $132.5 million to acquire intellectual property rights of the antitumor-associated mucin-1 ...
Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...
Hosted on MSN16d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mDaiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback